Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.6667.

GANX has been the topic of a number of analyst reports. Roth Mkm reissued a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Finally, Maxim Group increased their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently modified their holdings of GANX. Wealth Enhancement Advisory Services LLC bought a new position in Gain Therapeutics during the third quarter worth $28,000. JPMorgan Chase & Co. bought a new stake in Gain Therapeutics during the third quarter worth about $47,000. Benedict Financial Advisors Inc. lifted its position in Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after purchasing an additional 12,500 shares during the period. Apollon Wealth Management LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter valued at $64,000. Finally, Oliver Luxxe Assets LLC bought a new position in shares of Gain Therapeutics in the 4th quarter valued at $65,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Stock Down 4.9%

Gain Therapeutics stock opened at $1.95 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The firm’s fifty day simple moving average is $2.95 and its 200-day simple moving average is $2.23. The company has a market capitalization of $75.00 million, a P/E ratio of -3.20 and a beta of 0.06.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). Sell-side analysts forecast that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.